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Abstract
Tuberculosis (TB) remains a pandemic affecting billions of people worldwide, thus stressing the need for new vaccines.
Defining the correlates of vaccine protection is essential to achieve this goal. In this study, we used the wild boar model for
mycobacterial infection and TB to characterize the protective mechanisms elicited by a new heat inactivated Mycobacterium
bovis vaccine (IV). Oral vaccination with the IV resulted in significantly lower culture and lesion scores, particularly in the
thorax, suggesting that the IV might provide a novel vaccine for TB control with special impact on the prevention of
pulmonary disease, which is one of the limitations of current vaccines. Oral vaccination with the IV induced an adaptive
antibody response and activation of the innate immune response including the complement component C3 and
inflammasome. Mycobacterial DNA/RNA was not involved in inflammasome activation but increased C3 production by a still
unknown mechanism. The results also suggested a protective mechanism mediated by the activation of IFN-c producing
CD8+ T cells by MHC I antigen presenting dendritic cells (DCs) in response to vaccination with the IV, without a clear role for
Th1 CD4+ T cells. These results support a role for DCs in triggering the immune response to the IV through a mechanism
similar to the phagocyte response to PAMPs with a central role for C3 in protection against mycobacterial infection. Higher
C3 levels may allow increased opsonophagocytosis and effective bacterial clearance, while interfering with CR3-mediated
opsonic and nonopsonic phagocytosis of mycobacteria, a process that could be enhanced by specific antibodies against
mycobacterial proteins induced by vaccination with the IV. These results suggest that the IV acts through novel mechanisms
to protect against TB in wild boar.
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Introduction
Tuberculosis (TB) caused by members of the Mycobacterium
tuberculosis complex affects more than 2.5 billion people worldwide
with approximately 9 million new cases reported every year [1].
The Bacillus Calmette-Gue´rin (BCG) vaccine has been widely
used for TB control [2]. However, BCG and other first-generation
vaccines do not prevent infection nor achieve sterile eradication,
but rather prime and/or boost infection control. Therefore, the
development of new safe vaccines is required to achieve full
protection in some areas and age groups, and particularly to
protect against pulmonary disease and infection rather than from
active TB [2,3]. Additionally, the correlates of protection for TB
and BCG vaccines are poorly defined and constitute essential
information for the development of improved vaccines [2,4–6].
Recently, we developed a model for mycobacterial infection and
TB using Eurasian wild boar (Sus scrofa) [7,8]. Wild boar are
susceptible to mycobacterial infection and reproduce some of the
clinical symptoms observed in human TB cases such as lung
pathology and latent infection [9,10]. Molecular characterization
of host-pathogen interactions identified S. scrofa genes such as
methylmalonyl CoA mutase (MUT), complement component 3
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(C3) and other innate and adaptive immune response genes
involved in resistance to mycobacterial infection [11–16].
Wild boar are natural reservoir hosts for Mycobacterium bovis in
some regions and thus vaccination strategies are being developed
for TB control in this species [7,8,10]. Recently, parenteral and
oral vaccination with a heat-inactivated M. bovis vaccine (IV)
protected wild boar against TB with special reduction in thorax
tuberculous lesions [8]. These results suggested that oral vaccina-
tion with the IV might constitute a novel approach for TB control
with the aim of preventing or drastically reducing acquisition and
establishment of infection. However, as for other vaccines for TB
control, the protection mechanisms elicited by the IV remain
unclear and are the focus of this study. In these experiments, we
did not focus on a preconceived mechanism, but rather explored
the hypothesis that different mechanisms including adaptive and
innate immune responses may constitute possible correlates of
protection for the IV.
Materials and Methods
Ethics Statement
Animals were monitored daily by the veterinarians. Handling
procedures and sampling frequency were designed to reduce stress
and health risks for subjects, according to European (86/609) and
Spanish legislation (R.D. 223/1988, R.D. 1021/2005). For oral
vaccination, challenge and bleeding, restraint was not longer than
10 minutes/animal. When required in nervous or stressed animals,
wild boar and pigs were anesthetized prior to bleeding with
tiletamine-zolazepam (TZ) (3 mg/kg) and medetomidine (M)
(0.05 mg/kg). At the end of the experiment, animals were
anesthetized with the protocol described above followed by the
use of the captive bolt method.
During the experiment mini pigs were group housed in the
Biosafety Level 3 containment of the Animal Health Surveillance
Centre (VISAVET, Complutense University of Madrid, Spain).
The protocol was approved by the ‘‘Comunidad de Madrid’’
IACUC (Regional agriculture authority; permit number:
CM180112-01 (18/01/2012)). Wild boar were located in one
group in the Biosafety Level 3 containment of the Basque Institute
for Agricultural Research and Development (NEIKER-Tecnalia)
and the protocol was approved by the Committee on the Ethics of
Animal Experiments of the Regional Agriculture Authority
(Diputacio´n Foral de Vizcaya, Permit Number: BFA10.373 (27/
19/2010)).
Preparation of the IV
The M. bovis field isolate Neiker 1403 (spoligotype SB0339)
originally obtained from a naturally infected wild boar was used
for IV preparation. The isolate was cultivated for 2–3 weeks in
Middlebrook 7H9 medium enriched with OADC. Cells were
obtained after centrifugation at 2,5006g for 20 minutes at room
temperature (RT) and after two washes in PBS, the pellet was
resuspended in PBS and passed through an insulin syringe for
declumping. The optical density of the suspension was adjusted
with PBS to 5 McFarland units. Prior to inactivation, serial
dilutions (x10) were seeded in quadruplicate on 7H9 plates with
OADC solidified with agar in order to quantify the number of
colony forming units (cfu) in the inoculum. The inoculum was
inactivated in a shaking water bath at 81–83uC for 40 minutes.
Inactivated inoculum was cultured in BACTEC Mycobacterial
Growth Indicator Tubes supplemented as indicated by the
manufacturer (Becton Dickinson) and onto OADC agar solidified
7H9 plates in triplicate (100 ml each) to confirm the absence of
viable mycobacteria. The final IV preparation contained approx-
imately the equivalent of 107 cfu in 0.2 ml of PBS.
Purification and Characterization of Nucleic acids from
the IV
One ml of IV was pelleted and resuspended in 500 ml of Tri
Reagent (Sigma-Aldrich St. Louis MO, USA). The solution was
sonicated during 1 hr in 6 cycles of 10 minutes each and then
immediately subjected to continuous vortex mixing for 30 min
[17]. The lysate was left at room temperature for 4 hrs with
intermittent vortex mixing every 15 min. Total RNA was
extracted following manufacturer instructions. Two ml of IV were
treated with 40ml (80 units) of DNaseI in 0.2 ml of 10X DNase I
Buffer (Ambion Life Technologies, Grand Island, NY, USA) and
incubated at 37uC for 1 hr. Six ml of water and 0.8 ml of 10x
RNAse ONE buffer were then added in order to provide suitable
conditions for the RNAse ONE Ribonuclease enzyme (Promega,
Madison WI, USA). The reaction was incubated at 75uC for
10 min. Subsequently, 95 ml of RNAse ONE (10 units/ml) were
added to the reaction and incubated at 37uC for 3 hrs. Total RNA
was used to synthesize cDNA using random primers and the
Access RT-PCR system (Promega, Madison, WI, USA). Total
RNA and IV samples were characterized by RT-PCR using
oligonucleotide primers Mycgen-F: 59-AGAGTTT-
GATCCTGGCTCAG-39 and Mycgen-R: 59-TGCACA-
CAGGCCACAAGGGA-39 that amplify 16S rRNA from Myco-
bacterium tuberculosis complex [18] and the Access RT-PCR system
Table 1. Oligonucleotide primers and PCR conditions for M. bovis (IV isolate) genes.
Gene (Genbank
accession number) Upstream/downsteam primer sequences (59-39)
PCR annealing
temperature
PCR product size
(bp)
NADP-dependent alcohol
dehydrogenase C
(NADPAD) (P0A4X1)
GGTGGTCATATGAGCACTGTTGCCGCCTAC/
GGTGGTTGCTCTTCCGCACAGGGCTGAGATGTCGATGAC
56uC 1,041
glyceraldehyde-3-
phosphate dehydrogenase
(GAPDH) (P64179)
GGTGGTCATATGGTGACGGTCCGAGTAGGCATC/
GTGGTTGCTCTTCCGCAGAGCGACTTGCCGACCAGCGT
66uC 1,023
MPB83 (ACD61707) GGTGGTCATATGATCAACGTTCAGGCCAAA/
GGTGGTTGCTCTTCCGCACTGTGCCGGGGGCATCAGCAC
42uC 663
Universal stress protein
RV2623/MT2698 (NP_337200)
GGTGGTCATATGTCATCGGGCAATTCATCT/
GGTGGTTGCTCTTCCGCAAGTCAGCGACTCGCGTGCCAC
42uC 894
doi:10.1371/journal.pone.0098048.t001
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Table 2. Oligonucleotide primers and RT-PCR conditions for the analysis of mRNA levels.
GenBank accesion number Gene Primer sequences (59- 39) PCR annealing conditions
NM_214009 Complement component 3, SsC3-L: acaaattgacccagcgtagg 55uC, 30s
C3 SsC3-R: gcacgtccttgctgtactga
DQ913893 Interferon gamma, IFN-c SsIFNg-L: ttcagctttgcgtgactttg 55uC, 30s
SsIFNg-R: tcctttgaatggcctggtta
NM_214055 Interleukin 1-beta, IL-1b SsIL1beta-L: ccaaagagggacatggagaa 55uC, 30s
SsIL1beta-R: ttatatcttggcggcctttg
NM_214405 Methylmalonyl CoA SsMUT-L: gtttgccaacggtgaaaagt 55uC, 30s
mutase, MUT SsMUT-R: aatgagcttcaaggcagcat
JN391525 Interferon beta, IFN-b Ss-IFNBF: tcagaagctcctgggacagt 55uC, 30s
Ss-IFNBR: atctgcccatcaagttccac
AY373815 Perforin 1, PRF1 Ss-PerfF: gctccaccctgagttcaaga 57uC, 30s
Ss-PerfR: agtcctccacctccttggat
NM_001001532 Chemokine (C-C motif) Ss-CCR7F: tgtgcttcaagaaggacgtg 57uC, 30s
receptor 7, CCR7 Ss-CCR7R: aagggtcaggaggaagagga
KF280280 Toll-like receptor adaptor Hs-TRIFF: caggagcctgaggagatgag 55uC, 30s
molecule 1, TRIF Hs-TRIFR: ctgggtagttggtgctggtt
KF280281 NLR family, pyrin domain Hs-NLRP3F: cttctctgatgaggcccaag 55uC, 30s
containing 3 (NLRP3) Hs-NLRP3R: gcagcaaactggaaaggaag
NM_001206359 Glyceraldehyde-3- Ss-GAPHDF: gtcggttgtggatctgacct 55uC, 30s
phosphate dehydrog., GAPHD Ss-GAPHDR: agcttgacgaagtggtcgtt
EU077229 Myeloid differentiation Ss-MyD88F: cggaggagatgaacttcgag 56uC, 30s
Prim.-respon. prot. 88, MYD88 Ss-MyD88R: actttcggcagtcctcttca
DQ452569 b-actin Ss-BactinF: ggacctgaccgactacctca 55uC, 30s
Ss-BactinR: ggcagctcgtagctcttcat
AY008846 Cyclophilin SsCyclophilin-L: agcactggggagaaaggatt 55uC, 30s
SsCyclophilin-R: cttggcagtgcaaatgaaaa
doi:10.1371/journal.pone.0098048.t002
Figure 1. Oral vaccination with IV protects wild boar against mycobacterial infection. (A) Lesion score, (B) culture score and (C) thorax
culture score in vaccinated (N = 7) and control (N = 8) wild boar. Solid lines show the median values. Values were compared between groups by
Student’s t-test with unequal variance (*P#0.005).
doi:10.1371/journal.pone.0098048.g001
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(Promega, Madison, WI, USA). Amplicons were cloned and six
independent clones were sequenced for analysis. The evolutionary
history was inferred using the Neighbor Joining method [19] in
MEGA5 (http://www.megasoftware.net). Blasting against nonre-
dundant sequence database (nr) was done using blastn (http://
blast.ncbi.nlm.nih.gov/Blast.cgi). Nucleotide sequences were
aligned using the program AlignX (Vector NTI Suite V 5.5,
InforMax, North Bethesda, MD, USA).
To characterize the effect of mycobacterial DNA/RNA in the
IV, four mini pigs were randomly allocated to two groups of two
animals each and orally vaccinated at days 1 (T0) and 28 with
2 ml of the IV depleted of mycobacterial DNA and RNA (IV-
DNA/RNA) and IV. One month after last vaccination (T1),
animals were challenged with 5 ml of a suspension containing
105 cfu of an M. bovis field strain and then euthanized four months
after challenge (T2) [7,8]. Oral mucosa and blood samples were
collected to compare oral mucosa and peripheral blood mononu-
clear cells (PBMC; Buffy coat) C3 mRNA levels and serum C3
protein and cytokine levels between animals vaccinated with IV
and IV-DNA/RNA.
Wild Boar Vaccination and Challenge
Fifteen 3–4-month-old wild boar piglets were bought in a
commercial farm known to be free of mycobacterial lesions at
slaughter and with a fully negative ELISA test [20]. The animals
were housed in class III bio-containment facilities where they had
ad libitum food and water. Wild boar piglets were randomly
assigned to two treatment groups, vaccinated (N = 7) and control
(N = 8). The IV (107 cfu) was delivered in baits designed for wild
boar piglets [21]. One bait per individual was introduced by hand
into the oral cavity, making sure the animal chewed and opened
the vaccine-containing vial. For challenge, 5 ml of a suspension
Figure 2. Oral vaccination with IV induces an antibody response in wild boar. (A) Identification by Western blot and mass spectrometry of
mycobacterial proteins recognized by antibodies in IV vaccinated wild boar. Identified proteins are indicated with arrows in Coomassie-blue stained
12% SDS-polyacrylamide gel (left panel) and Western blot with pooled sera from vaccinated and control animals at T0 and T2 (right panel) with 10 mg
IV proteins. MW, molecular weight markers. (B) Expression of recombinant proteins in E. coli. Ten mg of purified proteins were loaded per well in a 12%
SDS-polyacrylamide gel. Recombinant proteins are indicated with arrows. MW, molecular weight markers. (C) Western blot analysis of recombinant
mycobacterial proteins using pooled sera from IV vaccinated and control animals at T0, T1 and T2. Ten mg of purified proteins were loaded per well in
a 12% SDS-polyacrylamide gel. The position of the recombinant proteins is indicated with arrows. (D) Antibody levels against mycobacterial proteins
were determined by ELISA in serum samples from vaccinated and control animals and O.D.450 nm values (Ave+S.D.) were compared at each time point
between vaccinated and control groups by Student’s t-test with unequal variance (*P#0.05). (E, F) Correlation analysis between antibody levels
against NADPAD and MPB83 mycobacterial proteins in vaccinated and control animals and (E) lesion score or (F) culture score at T2 (N = 15).
doi:10.1371/journal.pone.0098048.g002
Heat Inactivated Vaccine against Tuberculosis
PLOS ONE | www.plosone.org 4 May 2014 | Volume 9 | Issue 5 | e98048
containing 105 cfu of an M. bovis field strain (spoligotype SB0339)
were administered by the oropharyngeal route as described in
previous experiments [7,8]. The animals were vaccinated at T0,
revaccinated at day 52, challenged at day 126 (T1) and necropsied
at day 255 (T2).
Sample Collection, Necropsy and Histopathology
Blood samples were collected at T0, T1 and T2 time points for
RNA extraction from PBMC and serum preparation. Animals
were anesthetized by intramuscular injection of zoletil, and
euthanized by captive bolt. A thorough postmortem examination
was done to detect the presence of macroscopic lesions. Samples
for culture were immediately processed and copies frozen at
280uC for RNA isolation. Tonsils, lymph nodes, lung (each lobe
considered separately), spleen, and ileocecal valve were carefully
inspected for TB-compatible lesions and cultured. When suspi-
cious lesions were observed in liver, kidney and lymph nodes from
other locations, samples from these tissues were also cultured. TB-
compatible lesions were classified based on lesion distribution and
lesion intensity, and scored as previously described [7]. Samples of
individual tissues were fixed in 10% buffered formalin, embedded
in paraffin, sectioned at 4 mm, and stained with hematoxylin–eosin
by use of standard procedures. Additional sections of tissues with
lesions indicative of TB were stained by Ziehl–Neelsen procedure
to detect the presence of acid-fast organisms.
Microbiology
All samples were cultured and spoligotyped in order to confirm
the strain as previously described [8]. We defined a culture score
for M. bovis infection as the number of lymph nodes or organ
samples yielding a M. bovis isolate, of the total number of culture
attempts (N$17 samples cultured per animal; score range 0–17).
Infection levels in different samples were categorized according to
the number of colonies per tube as follows: less than 10 colonies,
between 10 and 50 colonies and more than 50 colonies [8].
Figure 3. Oral vaccination with IV activates innate immune response in wild boar. (A) Comparison of PBMC mRNA levels between
vaccinated (N = 7) and control (N = 8) animals. (B) Comparison of PBMC mRNA levels between control animals with lower (N = 5) and higher (N = 3)
tuberculous lesion score. The mRNA levels of selected genes were analyzed by real-time RT-PCR in PBMC of vaccinated and control wild boar
collected at T0 (day 1, before vaccination), T1 (day 126, before challenge) and T2 (day 255 at necropsy). The mRNA levels were normalized against S.
scrofa cyclophilin, b-actin and GAPHD and normalized Ct values were represented as Ave+S.D. and compared between groups by Student’s t-test
with unequal variance (*P#0.05). (C) Serum C3 protein levels (mg/ml) were determined by ELISA in vaccinated and control wild boar at T0, T1 and T2
and compared between groups by Student’s t-test with unequal variance (P.0.05). (D) The difference in serum C3 protein levels (mg/ml) determined
by ELISA in vaccinated and control wild boar was calculated between T2 and T1 and represented as Ave6S.D. (E) Serum cytokine protein levels were
determined using the Quantibody porcine cytokine array in vaccinated (N = 7) and control (N = 8) wild boar at T0, T1 and T2, represented as Ave+S.D.
and compared between groups by Student’s t-test with unequal variance (*P#0.05).
doi:10.1371/journal.pone.0098048.g003
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Serological Analyses
Antibody response. Serum samples were tested for antibod-
ies against purified bovine tuberculin protein derivative (bovine
PPD; CZ Veterinaria, Porrin˜o, Spain) using an in-house ELISA
with Protein G (Calbiochem, Merck KGaA, Darmstadt, Germany)
conjugate as described by Boadella et al. [20]. Samples with E%
(E% = (sample O.D.450 nm/26mean negative control
O.D.450 nm)x100) .100 were considered positive. Antibodies
against mycobacterial GAPDH, NADPAD, MPB83, Rv2623
recombinant proteins were tested with the same ELISA described
before but coating the plates with 1 mg/well. DPPBovidTB and
DPPVetTB were used to test serum samples against DPP as
previously described [22]. The presence and intensity of either the
sole T band (a mixture of MPB70 and MPB83 proteins) of the
DPPBovidTB or the 2 separate test bands (T1, MPB83 antigen;
T2, CFP10/ESAT-6 fusion protein) of the DPPVetTB, were
evaluated by a DPP optical reader (in relative light units, RLU).
Reactivity above the cut-off value of 5.0 RLU in any of the test
bands was considered a positive result for the presence of antibody
[23].
Complement component 3. For the quantitative determi-
nation of pig C3 protein concentration in serum samples, a
commercially available sandwich ELISA was used (Pig Comple-
ment C3 ELISA kit, CUSABIO, Wuhan, China). Serum samples
and standards were analyzed following the manufacturer’s
instructions. Data was linearized by a standard curve and
regression analysis was used to determine sample C3 concentra-
tions in mg/ml.
Cytokines. The cytokine concentration in pooled sera was
determined at T0, T1 and T2 using the Quantibody porcine
cytokine array (RayBiotech Inc, Norcross, GA, USA), an array-
based multiplex ELISA system for the simultaneous quantitative
measurement of multiple cytokines. Using this system, standard
cytokines and samples were assayed in each array simultaneously
Figure 4. Mycobacterial DNA and RNA in the IV increase C3 expression levels. (A) Total RNA (4 mg) extracted from the IV or IV (2 ml) were
subjected to different treatments and analyzed by agarose gel electrophoresis after RT-PCR for the amplification of Mycobacterium spp. 16S rRNA. (B)
Total RNA extracted from the IV was treated with DNase I and/or RNase and used for cDNA synthesis using random primers 16S rRNA PCR. (C) Radial
un-rooted tree of the 16S rRNA phylogenetic analysis using Neighbor Joining. Mycobacterium species and sequence Genbank accession numbers are
shown. (D) Alignment of 16S rRNA sequences from the same mycobacteria used in the phylogenetic analysis to show characteristic single nucleotide
polymorphisms in the vaccination isolate (M. bovis (IV)). (E) C3 mRNA levels in the oral mucosa and PBMC at T2. (F) Serum C3 protein levels in pigs
vaccinated with the IV and IV-DNA/RNA determined by ELISA at T0, T1 and T2. The mRNA levels were normalized against S. scrofa cyclophilin, b-actin
and GAPHD. Normalized Ct values and protein levels (mg/ml) were represented as Ave+S.D. and compared between groups by Student’s t-test with
unequal variance (*P#0.05).
doi:10.1371/journal.pone.0098048.g004
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through a sandwich ELISA procedure, following the recommen-
dations of the manufacturer. The signals were visualized using a
Gene Pix 4100A laser scanner (Molecular Devices, Sunnyvale,
CA, USA) and data were extracted by GenePix Pro 6 software
(Molecular Devices). Finally, the quantitative data analysis was
performed using the Quantibody Q-Analyzer software (RayBio-
tech Inc). Cytokine concentration was expressed in pg/ml and two
replicates were performed for each sample.
Identification of Mycobacterial Proteins Recognized by
Vaccinated Animals
The IV proteins were analyzed using denaturing SDS-PAGE
with a 12% PAGEgelTM SDS cassette gel (PAGE-gel Inc., San
Diego, CA, USA) under reducing conditions. The bands were
visualized by Expedeon’s InstantBlue staining. Electrophoretic
transfer of proteins from gels to nitrocellulose membranes
(Schleicher & Schuell, PROTRAN BA85, Dassel, Germany) for
Western blot analysis was carried out in a Minie-Genie
Electroblotter semi-dry transfer unit (Idea Scientific, Corvallis,
OR, USA) according to the manufacture’s protocol. Membranes
were blocked with 5% (w/v) skim milk overnight at 4uC, and then
washed three times in TBS (100 mM Tris-base, 150 mM NaCl,
pH 7.5) and incubated for 1 hr with boar sera (1:200 dilution in
TBS). Membranes were then washed three times with TBS and
incubated with anti-pig IgG peroxidase conjugate (Sigma-Aldrich,
St. Louis, MO, USA) diluted 1:1000 for 1.25 hr at room
temperature. After washing the membranes with TBS, color was
developed using tetramethylbenzidine (TMB)-stabilized substrate
for horseradish peroxidase (Promega, Madison, WI, USA).
Proteins recognized by sera from animals vaccinated with the
IV were visualized by Coomassie Brilliant Blue R-250 staining,
excised, cut into cubes (262 mm) and digested overnight at 37uC
with 60 ng/ml trypsin (Promega, Madison, WI, USA) at 5:1
protein:trypsin (w/w) ratio in 50 mM ammonium bicarbonate,
pH 8.8 containing 10% (v/v) acetonitrile [24]. The resulting
tryptic peptides from each band were extracted by 30 min
incubation in 12 mM ammonium bicarbonate, pH 8.8. Trifluor-
oacetic acid was added to a final concentration of 1% and the
peptides were finally desalted onto C18 ProteaTips (Protea
Biosciences, Inc., Morgantown, WV, USA), dried-down and
Figure 5. Oral vaccination with IV increases serum IFN-c levels and CD8+/CD4+ T cell ratio. (A) Serum IFN-c protein levels were
determined using the Quantibody porcine cytokine array in vaccinated (N = 7) and control (N = 8) wild boar at T0, T1 and T2, represented as Ave+S.D.
and compared between groups by Student’s t-test with unequal variance (*P#0.05). (B) Flow citometry analysis of wild boar blood samples.
Representative flow citometry profiles of blood cell populations and CD4+/CD8+ T cell counts in vaccinated and control wild boar. (C) The CD4+/
CD8+ T cell ratio was determined in vaccinated (N = 7) and control (N = 8) wild boar at T1, represented as Ave+S.D. and compared between groups by
Student’s t-test with unequal variance (*P#0.05). (D) Simplified model for the generation of T cell effector responses in wild boar vaccinated with the
IV. Vaccine antigens are processed and presented by DCs associated to MHC class I and/or class II molecules. CD8+ T cells recognize MHC I-peptide
complexes and differentiate into IFN-c secreting cells capable of killing infected cells or pathogens. The mechanism of CD8+ T cell differentiation
mediated by CD4+ T cells may not be activated in wild boar vaccinated with the IV.
doi:10.1371/journal.pone.0098048.g005
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stored at 20uC until mass spectrometry analysis. The protein digest
was resuspended in 0.1% formic acid and analyzed by RP-LC-
MS/MS using a Surveyor LC system coupled to an ion trap LCQ
Fleet mass spectrometer (Thermo Scientific, San Jose, CA, USA).
The LCQ was programmed to perform a data-dependent MS/
MS scan on the 3 most intense precursors detected in a full scan
from 400 to 1600 amu, using an isolation width of 3 amu,
normalized collision energy of 30%, and dynamic exclusion
applied during 3 min periods. Protein identification was carried
out using the SEQUEST algorithm (Proteome Discoverer 1.1,
Thermo Scientific). Database search was performed against the
Actinobacteria database downloaded from the Protein Knowl-
edgebase (UniProtKB; http://www.uniprot.org). The following
constraints were used for the searches: tryptic cleavage after Arg
and Lys, up to two missed cleavage sites, and tolerances of 1 Da
for precursor ions and 0.8 Da for MS/MS fragment ions and the
searches were performed allowing optional Met oxidation and Cys
carbamidomethylation. A 1% false discovery rate (FDR) was the
criteria used for acceptance of peptides assignments and subse-
quent protein identification.
Cloning, Expression and Characterization of M. bovis
Recombinant Proteins
The genes encoding for proteins identified by Western blot and
proteomics analysis were amplified by PCR (Table 1), sequenced,
cloned into the pTXB1 expression vector (New England Biolabs,
Hitchin, Hertfordshire, UK) for expression in Escherichia coli. Three
independent clones were sequenced for analysis blasting against
nonredundant sequence database (nr) using blastn (http://blast.
ncbi.nlm.nih.gov/Blast.cgi). For production of recombinant pro-
teins, each strain was propagated overnight in 10 ml cultures in
50-ml shaker flasks at 37uC. The cells were harvested by
centrifugation at 39006 g for 15 min at 4uC and cell samples of
1 g wet weight were resuspended in 5 ml of lysis buffer (100 mM
NaH2PO4, 10 mM Tris–HCl, 8 M Urea, pH 7.0) and disrupted
by sonication (Bandelin Sonoplus, Berlin, Germany). The cell
lysate was dialyzed against column buffer (100 mM NaH2PO4,
10 mM Tris–HCl, 4 M Urea, pH 7.0) and centrifuged at
10,0006g for 15 min at 4uC. The cell debris was discarded and
the clarified cell extract was loaded into chitin-affinity purification
columns (New England Biolabs). The elution was carried out with
3 column volumes of cleavage buffer (column buffer containing
50 mM DDT) for 16 h at 4uC. The eluted fractions were dialyzed
in PBS, pH 8.0 to remove the excess of thiol reagent. Recombi-
nant proteins were analyzed by SDS-PAGE and Western blot as
previously described.
In vitro Experiments
In vitro infection and analysis of M. bovis. The pig lung
alveolar macrophage cell line 3D4/31 [25] was kindly donated by
Figure 6. C3 mRNA and protein levels correlate with protection elicited by vaccination with the IV. (A) Correlation analysis between C3
mRNA levels in PBMC at T1 and lesion score (N = 15). (B) Correlation analysis between C3 mRNA levels in PBMC at T1 and culture score (N = 15). (C)
Correlation analysis between the difference in serum C3 protein levels between T1 and T2 and lesion score (N = 15). (D) Correlation analysis between
the difference in serum C3 protein levels between T1 and T2 and culture score (N = 15). The mRNA levels were normalized against S. scrofa
cyclophilin, b-actin and GAPHD.
doi:10.1371/journal.pone.0098048.g006
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Juan Jose´ Garrido Pavo´n (University of Co´rdoba, Spain) and
maintained at 37uC in a 5% CO2 atmosphere in RPMI 1640
supplemented with 10% FCS and 0.1 mM Non-essential amino
acids (Life Technologies, Paisley, UK). Approximately 26106 cells
were experimentally infected with M. bovis (SB0339 strain) at 5
multiplicities of infection (5 mycobacteria per cell). After a 3 h
incubation, free bacteria were removed by washing with PBS, then
cells were incubated for 48 h with different concentrations of C3
(without C3, 0 mg/ml; low C3 concentration, 26 mg/ml; and high
C3 concentration, 105 mg/ml) in the presence of 10% sera from
control wild boar, IV-vaccinated wild boar and rabbit IgGs raised
against recombinant mycobacterial proteins MPB83 and NAD-
PAD. All treatments were tested in duplicate. Nucleic acids from
cell cultures at zero and 48 h post infection were extracted with
Tri Reagent (Sigma Aldrich, St. Louis, MO) following manufac-
turer’s recommendations. DNA was used to determine mycobac-
terial infection levels by real-time PCR using two different targets.
The major immunogenic protein MPB70, a highly conserved gene
within the M. tuberculosis complex, was amplified using primers
mpb70-F (59-CTCAATCCGCAAGTAAACC-39) and mpb70-R
(59-TCAGCAGTGACGAATTGG-39). The insertion sequence
IS6110 was amplified using the commercial TaqVet M. tuberculosis
Complex Kit (LSI, Lissieu, France). The DNA values were
normalized against S. scrofa cyclophilin using the genNorm ddCT
method [26].
Characterization of gene expression in pig DCs. Blood
samples were collected from the retro-orbital venous sinus of
healthy pigs in tubes with heparin. PBMC were purified by
Lymphoprep (Axis-shield, Oslo, Norway) density gradient centri-
fugation as previously described [27]. Briefly, blood was diluted
1:2 in PBS (Life Technologies, Paisley, UK) and after centrifuga-
tion at 4006g for 40 min, the mononuclear cell fraction was
washed three times with PBS and then resuspended in RPMI 1640
medium (Life Technologies) supplemented with 20 mM HEPES
buffer, l-glutamine (2 mM), penicillin (200 IU/ml), streptomycin
(100 mg/ml), 2-mercaptoethanol (561025 M) and 5% foetal calf
Figure 7. C3 plays a role in mycobacterial infection and protection elicited by DCs incubated with the IV. (A–F) Pig lung alveolar
macrophages (cell line 3D4/31) were experimentally infected with M. bovis (SB0339 strain) at 5 mycobacteria per cell. After removing free bacteria, the
cells were incubated for 48 h with 0 mg/ml, 26 mg/ml or 105 mg/ml of C3 in the presence of 10% sera from (A,B) control wild boar, (C,D) vaccinated
wild boar and (E,F) rabbit IgGs raised against recombinant mycobacterial proteins MPB83 and NADPAD. DNA was used to determine mycobacterial
infection levels by real-time PCR of the major immunogenic protein MPB70. M. bovis infection levels (normalized DNA Ct values) were expressed as
(A,C,E) Ave6S.D. or (B,D,F) the difference between 48 and 0 h (delta 48-0 h) and compared between 0 and 48 hrs for each treatment by x2-test (*P#
0.05; N = 2). (G–I) Pig DCs were incubated for 48 h with different amounts of the IV (0, 106, 56106, 107, 26107, and 46107 cfu). After incubation, cells
were collected, washed with PBS and total RNA extracted for C3, IL-1b, TRIF and NLRP3 gene expression analysis by real-time RT-PCR. The mRNA levels
were normalized against S. scrofa cyclophilin, b-actin and GAPHD and normalized Ct values were represented as Ave+S.D. and compared with the
group incubated without the IV by Student’s t-test with unequal variance (*P#0.05; N = 6).
doi:10.1371/journal.pone.0098048.g007
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serum (Life Technologies). 56106 cells/ml were seeded into 25-
cm3 flasks (Thermo Scientific, Rockford, IL, USA) at 7 ml/flask.
The flasks were incubated at 37uC for 3 h and nonadherent cells
were removed. The adherent cell population was rinsed gently
with medium before fresh medium with cytokines was added. The
cytokines used were recombinant swine proteins GM-CSF at
50 ng/ml, IL-4 at 50 ng/ml and IFN-a at 0.8 U/ml (Invitrogen,
Carlsbad, CA, USA). Cytokines were added on the first day of
culture and one third of the culture volumes were replaced every
second day. After 5 days of culture the majority of the cells had
obtained a dendritic morphology. The cells were then removed
from the flasks by 5–15 min incubation on ice, washed 1–2 times
with culture medium and aliquoted in 24 well plates (76105 cells/
well). DCs were incubated for 48 h with different amounts of the
IV (0, 106, 56106, 107, 26107, and 46107 cfu/well; N = 6 per
treatment). After incubation, cells were collected, washed with PBS
and total RNA extracted for gene expression analysis by real-time
RT-PCR.
RNA Isolation and Real Time RT-PCR
Total RNA was extracted from wild boar and pig PBMC, pig
oral mucosa and DCs using TRI reagent (Sigma, Madrid, Spain)
and the RNeasy kit (Qiagen, Izasa, Madrid, Spain), respectively
following manufacturer’s recommendations. RNA was used for
real-time RT-PCR analysis of mRNA levels of selected genes in
individual samples. Selected genes are involved in innate immunity
(complement component 3, C3; NLR family, pyrin domain
containing 3, NLRP3; Toll-like receptor adaptor molecule 1,
TRIF; myeloid differentiation primary-response protein 88,
MYD88; interleukin 1-beta, IL-1b; interferon gamma, IFN-c; and
interferon beta, IFN-b), mucosal immunity (Perforin, PERF and
chemokine (C-C motif) receptor 7, CCR7), and methylmalonyl
CoA mutase, MUT (Table 1). Real-time RT-PCR was performed
with gene-specific primers (Table 2) using the One-Step RT-PCR
Kit with SYBR Green and the CFX thermal cycler (Bio-Rad,
Hercules, CA, USA) following manufacturer’s recommendations.
Control reactions were performed using the same procedures, but
without RT to monitor DNA contamination in the RNA
preparations and without RNA added to monitor contamination
of the PCR reaction. A dissociation curve was run at the end of
RT-PCR reaction to ensure that only one amplicon was formed
and that the amplicon denatured consistently at the same
temperature range for every sample [28]. The mRNA values
were normalized against S. scrofa cyclophilin, b-actin and GAPHD
using the genNorm ddCT method [26].
Flow Cytometry
Not coagulated wild boar whole blood (100 ml) was stained
simultaneously with 1 mg each of FITC-conjugated anti-pig CD4
and PE-conjugated anti-pig CD8 monoclonal antibodies (BD
Biosciences, Madrid, Spain) following the manufacturer recom-
mendations. After staining, erythrocytes were lysed using BD
FACS Lysing Solution (BD Biosciences) and washed. Flow
cytometry was performed on a FACScalibur flow cytometer (BD
Figure 8. Proposed mechanism for C3 induction in response to vaccination with the IV. The IV components are sensed by dendritic cells
through a surface Toll-like receptor (TLR), which triggers signaling cascades that lead to the transcription of genes encoding pro-inflammatory
cytokines such as pro-IL-1b mediated by NK-kB activation through TLR adaptor, MYD88 and NLRP3 inflammasome activation promoted by TLR
adaptor, TRIF. Bacterial DNA and RNA present in the IV may also induce signaling and NLRP3 inflammasome activation. NLRP3 activation converts
pro-IL-1b into its bioactive mature form, which in turns stimulates the production of C3 by different cell types.
doi:10.1371/journal.pone.0098048.g008
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Biosciences). Peripheral blood leukocytes were identified by their
characteristic scatter profile. The CD4+/CD8+ ratio was calcu-
lated as the number of CD4+ positive cells versus the number of
CD8+ positive cells.
Statistical Analyses
Lesion scores, culture scores, mRNA levels (normalized Ct
values), antibody levels (D.O.450 nm), C3 protein levels (mg/ml),
cytokine levels (pg/ml) and CD4+/CD8+ and CD8+/CD4+ T cell
ratios at T1 were compared between groups by Student’s t-test
with unequal variance (P = 0.05). M. bovis infection levels
(normalized DNA Ct values) were compared between 0 and
48 h for each treatment by x2-test (P = 0.05). Regression was used
to analyze the relation between lesion and culture scores and
serum antibody levels or C3 mRNA and serum protein levels. The
significance of the correlation (95% C.I.) was calculated using
Simple Interactive Statistical Analysis (SISA; http://www.
quantitativeskills.com/sisa/statistics/corrhlp.htm).
Results and Discussion
Oral Vaccination with the IV Protects Boar against
Mycobacterial Infection
Oral vaccination with the IV resulted in significantly (P,0.005)
lower lesion and culture scores in vaccinated wild boar (Figs. 1A
and 1B). The most dangerous and contagious mycobacterial
infection is located in the thorax and associated with pulmonary
disease. Thorax culture score was significantly lower (P,0.005) in
vaccinated than in control animals with high proportion of
vaccinated animals with zero culture score (71% versus 13% in
control animals) (Fig. 1C). These results suggested that the IV
might provide a novel vaccine for TB control with special impact
on the prevention of pulmonary disease, which is one of the
limitations of current vaccines [3].
Oral Vaccination with the IV Induces Antibody Response
The IV was administered to boar orally in the absence of
adjuvant. However, our first question focused on whether it
induced an antibody response associated with protection. Western
blot analysis of the IV proteins using sera from vaccinated and
control animals identified proteins recognized by vaccinated
animals only at T2 (bands 1–3; Fig. 2A), while other bands were
recognized by vaccinated animals at T0 and T2 (band 4; Fig. 2A)
or by both vaccinated and control animals (group of bands in G;
Fig. 2A). Bands 1–4 were extracted from the gel and proteins
identified by mass spectrometry. The results showed that band 1
corresponded to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Genbank accession number P64179), a cell surface
ligand that may be involved in mycobacterial adherence to DCs
and macrophages [29]. Band 2 was identified as NADP-dependent
alcohol dehydrogenase C (NADPAD) (P0A4X1) [30]. Band 3
contained two proteins, MPB83 (ACD61707) and the universal
stress protein Rv2623/MT2698 (NP_337200). MPB83 is a
secreted glycoprotein with homology to MPB70 [31,32] that has
been used for immunodiagnosis of M. bovis-infected cattle [33] and
as a candidate vaccine antigen against TB [34,35]. The universal
stress protein Rv2623/MT2698 is an ATP-binding protein
involved in a pathway that promotes M. tuberculosis persistent
infection [36] and its protein sequence is identical to the M. bovis
hypothetical protein Mb2656 (NP_856302). Band 4 was identified
as MPB70 (ACD61706), a secreted protein used in ELISA for the
diagnosis of cattle infected with M. bovis [33,37].
The genes encoding for proteins in bands 1–3 that were
identified in vaccinated animals at T2 only were cloned from the
IV isolate Neiker 1403, recombinant proteins produced in E. coli
(Fig. 2B) and used in ELISA and Western blot analysis of sera from
vaccinated and control animals (Figs. 2C and 2D). The results
showed that sera from control and vaccinated animals recognized
M. bovis recombinant proteins after infection at T2, suggesting a
response to infection that for most proteins was enhanced after
vaccination with the IV.
Antibody titers against PPDb, DPP and GAPDH, NADPAD,
MPB83, Rv2623 recombinant proteins showed differences
between vaccinated and control animals for NADPAD and
MPB83 at T2 only (Fig. 2D). Interestingly, although not
statistically significant (P = 0.2–0.4) both NADPAD and MPB83
antibody levels had the tendency to be higher in animals with
lower lesion and culture scores (Figs. 2E and 2F). These results
suggested that antibodies against these proteins might be involved
in the protective response elicited by the IV.
Oral Vaccination with the IV Activates Innate Immune
Response
The next question on the possible protective mechanisms
associated with the IV focused on the innate immune response.
Based on our previous results of differential gene expression in wild
boar in response to M. bovis infection and vaccination and results
from other groups [7,8,12,14,15,38,39], we selected for mRNA
analysis genes involved in innate immunity (complement compo-
nent 3, C3; NLR family, pyrin domain containing 3, NLRP3; Toll-
like receptor adaptor molecule 1, TRIF; myeloid differentiation
primary-response protein 88, MYD88; interleukin 1-beta, IL-1b;
interferon gamma, IFN-c; and interferon beta, IFN-b), mucosal
immunity (Perforin, PERF and chemokine (C-C motif) receptor 7,
CCR7), and methylmalonyl CoA mutase, MUT (Table 2).
The analysis of gene expression in wild boar PBMC showed that
C3, IL-1b, TRIF, NLRP3 and MYD88 mRNA levels were higher
after vaccination (T1) in vaccinated animals when compared to
controls (Fig. 3A), with no effect of vaccination on IFN-c, IFN-b,
PERF, CCR7 and MUT mRNA levels (data not shown). After
infection (T2), only C3 mRNA levels remained higher in
vaccinated animals (Fig. 3A). Comparison of control animals with
high (40–53; N = 3) and low (15–23; N = 5) tuberculous lesion
score (Fig. 1A), showed that as in previous experiments with
natural wild boar populations [13–15,40], C3 and MUT mRNA
levels were higher in less tuberculous animals at T1 (Fig. 3B).
Serum C3 protein levels did not show significant differences
between vaccinated and control animals due to animal-to-animal
variations (Fig. 3C), but a tendency towards increasing C3 levels
after infection was observed in vaccinated but not in control
animals (Fig. 3D).
Serum protein levels for pro-inflammatory cytokines IL-1b
(833644 vs. 266611 pg/ml in vaccinated and control animals,
respectively) and IL-6 (3165 vs. 860 pg/ml in vaccinated and
control animals, respectively) were higher in vaccinated animals at
T1 (Fig. 3E), with no significant differences in the levels of IL-4,
IL-8, IL-10, IL-12, GM-CSF, TGF-b1 and TNF-a (data not
shown). These results together with the induction of TRIF, NLRP3
mRNA levels in vaccinated animals suggested the activation of the
innate immune response including inflammasome in response to
the IV [39].
The IV contains Mycobacterial DNA and RNA that
Increase C3 Expression Levels in Vaccinated Animals
The results presented here suggested inflammasome activation
in response to the IV. However, this protective mechanism has
been mostly associated with live and not killed vaccines [39].
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Recently, prokaryotic messenger RNA was identified as viability-
associated pathogen-associated molecular patterns (vita-PAMPs)
involved in inflammasome activation and protection against live
bacteria [39]. Although wild boar were vaccinated orally with
inactivated mycobacteria, we characterized the presence and
possible role of mycobacterial DNA and RNA in the IV.
The results showed that the IV contains mycobacterial DNA
and RNA (Figs. 4A and 4B). Total RNA extracted from the IV
was equivalent to 0.45 mg/ml (260 nm/280 nm ratio = 1.85). The
sequence of the 16S rRNA amplicon had .99% identity (E = 0.0)
to other Mycobacterium spp. (Fig. 4C), but showed some distinctive
single nucleotide polymorphisms (Fig. 4D). In a preliminary
experiment, pigs were vaccinated with the IV and the IV depleted
of DNA and RNA (IV-DNA/RNA). The presence of only two
animals per group precluded from comparing lesion and culture
scores between animals vaccinated with the IV and the IV-DNA/
RNA. The analysis of TRIF and NLRP3 mRNA levels did not
show any difference between animals vaccinated with the IV and
the IV-DNA/RNA (data not shown), suggesting that bacterial
DNA/RNA were not involved in inflammasome activation in
response to the IV. However, the finding of higher C3 mRNA and
serum protein levels in pigs vaccinated with the IV when
compared to animals vaccinated with the IV-DNA/RNA
(Figs. 4E and 4F) suggested a role for mycobacterial DNA/RNA
in C3 production by a still unknown mechanism.
IFN-c Protein Levels Increased in Response to Oral
Vaccination with the IV
Vaccination with BCG has been shown to induce protection
against mycobacteria in humans, possums and mice [41–43] and
the IFN-c production by CD4+ T cells has been shown to play a
role in protection against TB after vaccination with BCG in
humans and mice [41,42]. IFN-c has been also shown to be
involved in protection against TB in infected individuals [44]. In
wild boar, IFN-c levels increase after parenteral BCG vaccination
but no correlation with protection was observed [8]. Although
IFN-c mRNA levels did not change in response to the IV, we next
focused on this mechanism due to its possible role in protection
against TB.
In our experiments, serum IFN-c levels were higher in
vaccinated animals at T1 and T2 when compared to controls
(Fig. 5A). This result suggested that, although differences were not
detected at the mRNA level, IFN-c protein levels increased in
vaccinated animals with the possible involvement of CD4+/CD8+
T cells [42,44]. The characterization of CD4+/CD8+ T cell
populations in vaccinated and control wild boar at T1 showed that
the majority of the cells were CD4+/CD8+ in both vaccinated and
control animals (Fig. 5B). However, the CD4+/CD8+ ratio was
calculated considering CD8+/CD42 and CD82/CD4+ cells
only and showed a higher CD4+/CD8+ ratio in control animals
(Fig. 5C). This result suggested a protective mechanism mediated
by IFN-c producing CD8+ T cells in response to vaccination with
the IV, without a clear role for Th1 CD4+ T cells (Fig. 5D). This
mechanism has been shown before in mice infected with M.
tuberculosis [44] and recent results questioned the role previously
attributed to IFN-c production by CD4+ T cells as a protective
correlate for BCG [4]. As shown before, inflammasome activation
in response to the IV led to secretion of IL-1b that results in an
acute inflammatory response inducing the production of down-
stream inflammatory cytokines such as IFN-c [45], suggesting an
additional mechanism explaining the higher IFN-c levels in wild
boar vaccinated with the IV when compared to controls.
C3 Plays a Role in Protection Elicited by Oral Vaccination
with the IV
The results obtained here showed that C3 levels increased in
response to the IV, probably regulated at the mRNA level.
Correlation analysis between C3 mRNA levels and lesion and
culture scores demonstrated a tendency towards higher C3 mRNA
levels in less tuberculous animals at T1 and T2 but not at T0
(Figs. 6A and 6B and data not shown) with statistically significant
correlation for lesion score (P = 0.05). The correlation between the
increase in serum C3 protein levels from T1 to T2 (DT22T1) and
lesion and culture scores demonstrated that the increase in C3
protein levels correlated with lower lesion (P = 0.05) but not
culture (P = 0.3) scores (Figs. 6C and 6D). These results together
with the increase in C3, IL-1b, TRIF and NLRP3 mRNA levels and
IL-1b and IFN-c protein levels in vaccinated animals, suggested
that vaccination with the IV induced a protective response
associated with the complement system (C3) and TRIF-mediated
NLRP3 (inflammasome) activation, both involved in bacterial
phagocytosis and clearance [46–49].
To test the role of C3 in protection elicited with the IV, an
in vitro experiment was conducted characterizing the effect of C3
alone or in combination with anti-IV antibodies on M. bovis
infection of cultured pig macrophages. The results showed that C3
in combination with sera from control wild boar increased
infection of pig macrophages (Figs. 7A and 7B), supporting a role
for the complement system in mycobacterial infection [48,49].
However, sera from IV vaccinated wild boar inhibited infection in
the absence of C3 but infection increased at higher C3 protein
levels (Figs. 7C and 7D), again suggesting a role for C3 during
mycobacterial infection and an inhibitory effect of anti-IV
antibodies. When specific antibodies against recombinant M. bovis
proteins recognized by IV-vaccinated wild boar were incubated in
combination with C3, a reduction in mycobacterial infection was
obtained (Figs. 7E and 7F). Similar results were obtained targeting
by PCR the mycobacterial gene MPB70 (Figs. 7A–7F) and of the
insertion sequence IS6110 (data not shown). In summary, these
results showed a role for C3 during M. bovis infection in the
absence of antibodies against mycobacterial proteins but suggested
a role for antibodies against IV proteins alone or in combination
with C3 in protection against infection.
Proposed Mechanism for the Protection Elicited by the IV
against TB
After completing the experiments described before, our
hypothesis was that the IV induces a protective immune response
triggered by dendritic cells (DCs) mimicking phagocyte response to
PAMPs [47]. To test this hypothesis, pig DCs were incubated with
different IV doses to characterize the mRNA levels for genes
known to be involved in cell response to PAMPs (TRIF, NLRP3,
IL-1b and C3; [47], upregulated in IV-vaccinated wild boar (TRIF,
NLRP3, IL-1b and C3; Fig. 4A) and which expression correlated
with protective response to the IV (C3; Figs. 4B, 6A and 6B). The
results showed that at an IV dose close to the vaccination dose
(1E+07 cfu), TRIF, NLRP3, IL-1b and C3 mRNA levels were
higher when compared to mock treated cells (Figs. 7G–7I).
These results support a role for DCs in triggering the immune
response to the IV through a mechanism similar to the phagocyte
response to PAMPs (Fig. 8). After oral vaccination in the absence
of adjuvants, DCs sense PAMPs present in the IV through a
surface Toll-like receptor (TLR), which triggers signaling cascades
that lead to the transcription of genes encoding pro-inflammatory
cytokines such as pro-IL-1b and IL-6 mediated by nuclear factor
kB (NF-kB) activation through TLR adaptor, MYD88 and
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NLRP3 inflammasome activation through TLR adaptor, TRIF by
a still unknown mechanism [47]. NLRP3 activation converts pro-
IL-1b into its bioactive mature form, which in turn stimulates the
production of C3 by DCs and other cells types [50–53].
Conclusions
In summary, C3 appears to play the central role in the
protective response elicited by the oral vaccination with the IV. C3
activation is required for both classical and alternative comple-
ment activation pathways [54]. The complement system has been
shown to be involved in mycobacterial pathogenesis. Mycobacte-
ria activate complement via classical, alternative and lectin
pathways [55]. M. tuberculosis activates the alternative complement
pathway and binds C3 protein, resulting in enhanced phagocytosis
by complement receptors (CR3) on human alveolar macrophages
[48,49]. This mechanism of C3 opsonophagocytosis by macro-
phages may result in the inhibition of bactericidal responses and
pathogen survival [48,49]. However, recently, the complement
receptor CR3-mediated nonopsonic phagocytosis of mycobacteria
has been proposed as the critical step for invasion and colonization
of macrophages during primary infection of inhaled mycobacteria
[56–58].
The upregulation of C3 in lymph nodes and tonsils correlates
with resistance to TB in wild boar [12,14,15]. As shown here, this
mechanism may be enhanced by vaccination with the IV to
protect animals against mycobacterial infection [7,8]. M. tubercu-
losis acquire opsonic C3 peptides by at least two distinct
mechanisms and can bind to CR3 at two distinct sites on the
receptor [59]. Opsonized M. tuberculosis binds CR3 at its C3bi
binding domain, and nonopsonized M. tuberculosis uses its
endogenous capsular polysaccharides to interact with the b-glucan
binding site near the C-terminus of CD11b [59]. Higher C3 levels
may allow increased opsonophagocytosis and effective bacterial
clearance, while interfering with CR3-mediated opsonic and
nonopsonic phagocytosis of mycobacteria, a process that could be
enhanced by specific antibodies against mycobacterial proteins
and/or lipids induced by vaccination with the IV [55]. Addition-
ally, the activation of IFN-c producing CD8+ T cells by MHC I
antigen presenting DCs may also contribute to the protection
elicited by the IV in wild boar.
These results suggest that the IV acts through novel mechanisms
to protect against TB in wild boar. However, additional
experiments are required to fully characterize these protective
mechanisms. Some of these mechanisms may be common to
different bacterial strains while others could be associated with
genetic signatures present in the bacterial genome of the IV strain
[5]. Finally, the impact of the IV for TB control in wild boar needs
to be demonstrated in field trials to consider possible applications
in other reservoir hosts and humans. If proven effective for TB
control, vaccination with the IV would have some advantages over
BCG or other live vaccines such as higher stability under field
conditions and safety.
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